Eliglustat
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09039 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 46 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | autosomal ichthyosis syndrome with fatal disease course | KG + DL |
| 2 | benign neoplasm of adrenal gland | KG + DL |
| 3 | polycystic kidney disease 3 with or without polycystic liver disease | KG + DL |
| 4 | gastrocutaneous syndrome | KG + DL |
| 5 | familial generalized lentiginosis | KG + DL |
| 6 | Moynahan syndrome | KG + DL |
| 7 | rhabdoid tumor | KG + DL |
| 8 | osteopathia striata-pigmentary dermopathy-white forelock syndrome | KG + DL |
| 9 | acromelanosis | KG + DL |
| 10 | congenital multiple café-au-lait macules-increased sister chromatid exchange syndrome | KG + DL |
| 11 | X-linked lymphoproliferative disease due to SH2D1A deficiency | KG + DL |
| 12 | leukonychia totalis-acanthosis-nigricans-like lesions-abnormal hair syndrome | KG + DL |
| 13 | renal-hepatic-pancreatic dysplasia | KG + DL |
| 14 | Joubert syndrome with renal defect | KG + DL |
| 15 | peripheral nerve schwannoma | KG + DL |
| 16 | karyomegalic interstitial nephritis | KG + DL |
| 17 | schwannoma of twelfth cranial nerve | KG + DL |
| 18 | thoracic malformation | KG + DL |
| 19 | sympathetic neurilemmoma | KG + DL |
| 20 | extracutaneous mastocytoma | KG + DL |
| 21 | Cushing disease due to pituitary adenoma | KG + DL |
| 22 | adult familial nephronophthisis-spastic quadriparesia syndrome | KG + DL |
| 23 | A20 haploinsufficiency | KG + DL |
| 24 | familial apolipoprotein C-II deficiency | KG + DL |
| 25 | proximal myopathy with extrapyramidal signs | KG + DL |
| 26 | microcystic/reticular schwannoma | KG + DL |
| 27 | trigeminal schwannoma | KG + DL |
| 28 | cholesteryl ester storage disease | KG + DL |
| 29 | bilateral parasagittal parieto-occipital polymicrogyria | KG + DL |
| 30 | immune dysregulation with inflammatory bowel disease | KG + DL |
| 31 | skeletal muscle disease | KG + DL |
| 32 | trichomegaly-retina pigmentary degeneration-dwarfism syndrome | KG + DL |
| 33 | axial spondylometaphyseal dysplasia | KG + DL |
| 34 | Wolman disease with hypolipoproteinemia and acanthocytosis | KG + DL |
| 35 | recessive X-linked ichthyosis | KG + DL |
| 36 | lower motor neuron syndrome with late-adult onset | KG + DL |
| 37 | neurocutaneous melanocytosis | KG + DL |
| 38 | amyotrophic lateral sclerosis, susceptibility to | KG + DL |
| 39 | inclusion myopathy | KG + DL |
| 40 | monomelic amyotrophy | KG + DL |
| 41 | amyotrohpic lateral sclerosis type 22 | KG + DL |
| 42 | autosomal dominant mitochondrial myopathy with exercise intolerance | KG + DL |
| 43 | neuroectodermal melanolysosomal disease | KG + DL |
| 44 | Mills syndrome | KG + DL |
| 45 | lethal arthrogryposis-anterior horn cell disease syndrome | KG + DL |
| 46 | Wolman disease | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.